Literature DB >> 14735248

[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].

U Berger1, R Hehlmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14735248     DOI： 10.1007/s00108-003-1085-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  5 in total

Review 1.  Current CML therapy: progress and dilemma.

Authors:  R Hehlmann
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

Review 2.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Authors:  F Bonifazi; A de Vivo; G Rosti; F Guilhot; J Guilhot; E Trabacchi; R Hehlmann; A Hochhaus; P C Shepherd; J L Steegmann; H C Kluin-Nelemans; J Thaler; B Simonsson; A Louwagie; J Reiffers; F X Mahon; E Montefusco; G Alimena; J Hasford; S Richards; G Saglio; N Testoni; G Martinelli; S Tura; M Baccarani
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

3.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Authors:  J Hasford; M Pfirrmann; R Hehlmann; N C Allan; M Baccarani; J C Kluin-Nelemans; G Alimena; J L Steegmann; H Ansari
Journal:  J Natl Cancer Inst       Date:  1998-06-03       Impact factor: 13.506

4.  Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Authors:  K Merx; M C Müller; S Kreil; T Lahaye; P Paschka; C Schoch; A Weisser; C Kuhn; U Berger; H Gschaidmeier; R Hehlmann; A Hochhaus
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

5.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.